Trial · NCT07442630
Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
NCT07442630, Phase 4, Active not recruiting, JW Pharmaceutical
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides. Trials, record NCT07442630. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07442630
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides
- NCT number
- NCT07442630
- Status
- Active not recruiting
- Phases
- Phase 4
- Enrollment
- 88 participants, actual
- Lead sponsor
- JW Pharmaceutical
- Conditions
- Hypercholesterolemia
- Interventions
- Pitavastatin 4mg, Ezetimibe 10 mg, Placebo (for Pitavastatin/Ezetimibe), Placebo (for Pitavastatin)
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage change from baseline in LDL Cholesterol at Week 8 after the first dose of study treatment | Baseline to week 8 | The unit of measure is percentage (%). The percentage change is calculated as: \[(Value at Week 8 - Value at Baseline) / Value at Baseline\] \* 100 |
| Secondary | Change from baseline in HDL Cholesterol at Weeks 8, 24, and 52 after the first dose of study treatment | Baseline to week 8, 24, 52 | Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL |
| Secondary | Change from baseline in Triglycerides at Weeks 8, 24, and 52 after the first dose of study treatment | Baseline to week 8, 24, 52 | Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL |
| Secondary | Change from baseline in LDL Cholesterol at Weeks 8, 24, and 52 after the first dose of study treatment | Baseline to week 8, 24, 52 | Change = (Value at Week 8, 24, or 52) - (Value at Baseline), Unit of measure: mg/dL |
| Secondary | Change from baseline in Non-alcoholic Fatty Liver Disease Liver Fat Score (NLFS) at Weeks 24 and 52 | Baseline to week 24, 52 | The NLFS is a calculated score used to estimate liver fat content. The change is calculated as (Value at Week 24 or 52) - (Value at Baseline). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07442630
GET https://conductscience.org/api/trials/v1/NCT07442630/registered